Since our population pharmacokinetic model showed AGP was a significant covariate decreasing gefitinib CL/F, pharmacokinetic property at the time of ILD occurrence would be described by AGP, if AGP at the time of ILD occurrence was determined. The gene discussed is ATP5MK; the disease is interstitial lung disease.